{"organizations": [], "uuid": "ba5b92b75113db74432f2376f1bc3149da03bff2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-axs-02-in/brief-axsome-therapeutics-says-axs-02-independent-data-monitoring-committee-recommends-continuation-of-coast-1-trial-idUSFWN1P40CV", "country": "US", "domain_rank": 408, "title": "BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T14:23:00.000+02:00", "replies_count": 0, "uuid": "ba5b92b75113db74432f2376f1bc3149da03bff2"}, "author": "", "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-axs-02-in/brief-axsome-therapeutics-says-axs-02-independent-data-monitoring-committee-recommends-continuation-of-coast-1-trial-idUSFWN1P40CV", "ord_in_thread": 0, "title": "BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-axsome therapeutics says axs-02 independent data monitoring committee", "sentiment": "negative"}, {"name": "data monitoring committee recommends continuation of coast-1 trial reuters", "sentiment": "none"}, {"name": "axsome therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 9, 2018 / 12:25 PM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial Reuters Staff 1 Min Read \nJan 9 (Reuters) - Axsome Therapeutics Inc: \n* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL \n* AXSOME THERAPEUTICS- IN CREATE-1 TRIAL, AXS-02 TREATMENT RESULTED IN SIGNIFICANT REDUCTION OF SERUM CTX AS COMPARED TO PLACEBO \n* AXSOME THERAPEUTICS- IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION IN BOTH STUDIES, CONFIRMED THAT AXS-02 WAS SAFE AND GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-09T14:23:00.000+02:00", "crawled": "2018-01-09T14:41:10.020+02:00", "highlightTitle": ""}